StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Valeant (VRX) FDA Catalysts a Mixed Bag and Expected, Now Focus on Earnings - Wells Fargo
July 20, 2016 6:52 AM
Wells Fargo analyst David Maris weighed in on Valeant Pharmaceuticals (NYSE: VRX) after a FDA AdCom recommend Brodalumab approval with ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Rodman & Renshaw Reiterates Buy Rating on Valeant (VRX)
July 20, 2016 8:02 AM
Valeant (VRX) Pipeline Developments 'Positive', But In-Line with Expectations - BMO Capital
July 20, 2016 7:40 AM
Valeant (VRX) Oral Relistor Approval a 'Slight Positive' - RBC Capital
July 20, 2016 6:47 AM
Valeant Pharma (VRX), Progenics Pharmaceuticals (PGNX) Granted FDA Approval for RELISTOR
July 19, 2016 6:06 PM
